

Prior Authorization DRUG Guidelines

SUCRAID (Sacrosidase)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Catherine Sanders, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

Sacrosidase is a naturally-occurring gastrointestinal enzyme derived from baker's yeast (*Saccharomyces cerevisiae*) which breaks down the disaccharide sucrose to its monosaccharide components. Hydrolysis is necessary to allow absorption of these nutrients.

Pre-Authorization Criteria:

Sacrosidase is indicated as oral replacement therapy of the genetically determined sucrose deficiency, as seen in congenital sucrose-isomaltase deficiency (CSID).

VCHCP requires that Sacrosidase be prescribed by a physician specializing in the condition being treated.

Prescribing and Access Restrictions:

Sucraid® is not available in retail pharmacies or via mail-order pharmacies. To obtain the product, please refer to <http://www.sucraid.net/how-to-order-sucraid> or call 1-866-740-2743.

Dosing: Adult:

Congenital sucrose-isomaltase deficiency (CSID): Oral: 17,000 units (2 mL) per meal or snack. Doses should be diluted with 2-4 oz of cold or room temperature water, milk, or formula. Approximately one-half of the dose should be taken before and the remainder of a dose taken during each meal or snack.

Dosing: Pediatric:

Congenital sucrose-isomaltase deficiency (CSID):

Infants \geq 5 months and Children \leq 15 kg: Oral: 8500 units (1 mL) per meal or snack. Doses should be diluted with 2-4 oz of cold or room temperature water, milk, or formula. Approximately one-half of the dose should be taken before and the remainder of a dose taken during each meal or snack.

Children $>$ 15 kg and Adolescents: Refer to adult dosing.

Dosing: Geriatric:

Refer to adult dosing.

Dosing: Renal Impairment:

No dosage adjustment provided in manufacturer's labeling.

Dosing: Hepatic Impairment:

No dosage adjustment provided in manufacturer's labeling.

Dosage Forms: U.S.:

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Oral:

Sucraid: 8500 units/mL (118 mL) [contains papain]

Generic Equivalent Available: U.S.-No

Administration:

Dilute dose in 2-4 oz of cold or room temperature water, milk, or formula; avoid fruit juices or warm or hot food/liquids (may lower potency).

Adverse Reactions:

Headache, insomnia, nervousness, dehydration, abdominal pain, constipation, diarrhea, nausea, vomiting.

Other Serious Less Common Reactions: Hypersensitivity reactions, wheezing

Contraindications:

Hypersensitivity to yeast, yeast products, glycerin (glycerol) or papain

References:

1. Blanco C, Carrillo T, Castillo R, et al, "Latex Allergy: Clinical Features and Cross-Reactivity With Fruits," *Ann Allergy*, 1994, 73(4):309-14. [PubMed 7943998]
2. Focke M, Hemmer W, Wohrl S, et al, "Cross-reactivity Between *Ficus benjamina* Latex and Fig Fruit in Patients With Clinical Fig Allergy," *Clin Exp Allergy*, 2003, 33(7):971-7. [PubMed 12859455]
3. Freye HB, "Papain Anaphylaxis: A Case Report," *Allergy Proc*, 1988, 9(5):571-4. [PubMed 3234762]
4. Isola S, Ricciardi L, Saitta S, et al, "Latex Allergy and Fruit Cross-Reaction in Subjects Who Are Nonatopic," *Allergy Asthma Proc*, 2003, 24(3):193-7. [PubMed 12866323]
5. Treem WR, McAdams L, Stanford L, et al, "Sacrosidase Therapy for Congenital Sucrose-Isomaltase Deficiency," *J Pediatr Gastroenterol Nutr*, 1999, 28(2):137-42. [PubMed 9932843]
6. www.uptodate.com: Sacrosidase: Drug Information

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review